GSK3B and Alzheimer disease: Synthetic and semi-synthetic GSK3β inhibitors, including 17 β-carboline-1,2,3-triazole hybrids (compound 21), oxazole-4-carboxamide/butylated hydroxytoluene hybrids (compound KWLZ-9e), 1,2,4-thiadiazolidine-3,5-dione derivatives (compound 10a), novel coumarin derivatives (compound 30), and novel α-carboline derivatives (compound ZCH-9), exhibit remarkable anti-AD and therapeutic benefits (Liu et al., 2022a; Luo et al., 2023; Dong et al., 2023; Liu et al., 2022b; Chen H. et al., 2022).